Koen van Besien

19.7k total citations · 1 hit paper
354 papers, 12.0k citations indexed

About

Koen van Besien is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Koen van Besien has authored 354 papers receiving a total of 12.0k indexed citations (citations by other indexed papers that have themselves been cited), including 216 papers in Hematology, 128 papers in Oncology and 95 papers in Genetics. Recurrent topics in Koen van Besien's work include Hematopoietic Stem Cell Transplantation (163 papers), Lymphoma Diagnosis and Treatment (73 papers) and Acute Myeloid Leukemia Research (55 papers). Koen van Besien is often cited by papers focused on Hematopoietic Stem Cell Transplantation (163 papers), Lymphoma Diagnosis and Treatment (73 papers) and Acute Myeloid Leukemia Research (55 papers). Koen van Besien collaborates with scholars based in United States, Netherlands and France. Koen van Besien's co-authors include Sergio Giralt, Donna Przepiorka, Rakesh Mehra, Börje S. Andersson, Issa F. Khouri, Wendy Stock, James Gajewski, Andrew Artz, Richard E. Champlin and Paolo Anderlini and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Biological Chemistry.

In The Last Decade

Koen van Besien

339 papers receiving 11.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy

1997 909 citations Koen van Besien, Issa F. Khouri et al. Blood profile →

Peers

Countries citing papers authored by Koen van Besien

Since Specialization

Citations

This map shows the geographic impact of Koen van Besien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Koen van Besien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Koen van Besien more than expected).

Fields of papers citing papers by Koen van Besien

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Koen van Besien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Koen van Besien. The network helps show where Koen van Besien may publish in the future.

Co-authorship network of co-authors of Koen van Besien

This figure shows the co-authorship network connecting the top 25 collaborators of Koen van Besien. A scholar is included among the top collaborators of Koen van Besien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Koen van Besien. Koen van Besien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I Study Results of UF-Kure19, a CAR-T Product Manufactured in Less Than 1 Day, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma 2024 ·Blood ·Changchun Deng, Paolo F. Caimi, Umar Farooq, (unknown), (unknown), Jane Reese, (unknown), Daniel P. Caley, (unknown), Koen van Besien, Marcos de Lima, Arun Kumar Arunachalam, J. Joseph Melenhorst, David N. Wald	1
2	Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol 2024 ·Blood Advances ·Sarah Nikiforow, Jennifer Whangbo, Ran Reshef, Donald E. Tsai, Nancy Bunin, Rolla Abu‐Arja, Kris M. Mahadeo, Wen‐Kai Weng, Koen van Besien, David M. Loeb, Sunita D. Nasta, Eneida R. Nemecek, (unknown), Yan Sun, (unknown), Justin T. Wahlstrom, Aditi Mehta, Laurence Gamelin, Rajani Dinavahi, Susan E. Prockop	8
3	Low Dose Total Body Irradiation Improves CD19 CAR-T Expansion, Persistence, and Trafficking, Leading to Enhanced Efficacy in Large B-Cell Lymphoma 2023 ·Blood ·(unknown), (unknown), Mayumi Sugita, Takahiro Yamazaki, Leandro Marcelo Martinez, (unknown), (unknown), Paul G. Pagnini, Tsiporah B. Shore, Olivier Boyer, Renier J. Brentjens, Koen van Besien, Lorenzo Galluzzi, Silvia C. Formenti, J. Martinet, Mónica L. Guzmán	2
4	Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia 2023 ·Cell Death and Disease ·Mayumi Sugita, Takahiro Yamazaki, (unknown), J. Martinet, Jean‐Baptiste Latouche, Encouse B. Golden, Olivier Boyer, Koen van Besien, Silvia C. Formenti, Lorenzo Galluzzi, Mónica L. Guzmán	22
5	Adenovirus viremia after in vivo T-cell depleted allo-transplant in adults: low lymphocyte counts are associated with uncontrolled viremia and fatal outcomes 2021 ·Leukemia & lymphoma ·(unknown), Rosemary Soave, Zhengming Chen, Tsiporah B. Shore, Sebastian Mayer, Adrienne A. Phillips, (unknown), (unknown), Hanna Rennert, (unknown), (unknown), Thomas J. Walsh, Catherine B. Small, Rosy Priya Kodiyanplakkal, Markus Plate, Michael J. Satlin, Koen van Besien	2
6	Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic 'Off-the-Shelf' CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL 2021 ·Blood ·Nitin Jain, Hagop M. Kantarjian, Scott R. Solomon, Fiona He, Craig S. Sauter, Christopher R. Heery, Alan F. List, Mark Johnson, Yu Lou, Monika Vainorius, Koen van Besien, Adam J. Olszewski, Anthony S. Stein, Bijal Shah	14
7	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma 2020 ·Journal for ImmunoTherapy of Cancer ·Sattva S. Neelapu, Sherry Adkins, Stephen M. Ansell, Joshua Brody, Mitchell S. Cairo, Jonathan W. Friedberg, Justin Kline, Ronald Levy, David L. Porter, Koen van Besien, Michael E. Werner, Michael R. Bishop	11
8	Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes 2018 ·Biology of Blood and Marrow Transplantation ·Usama Gergis, (unknown), Tsiporah B. Shore, Sebastian Mayer, Adrienne A. Phillips, Jingmei Hsu, Gail J. Roboz, Ellen K. Ritchie, Joseph M. Scandura, Sang‐Min Lee, Pinkal Desai, Michael S. Samuel, (unknown), (unknown), (unknown), (unknown), Ludy Dobrila, Andromachi Scaradavou, Koen van Besien	1
9	CCR5 delta32 Cord & Haploidentical Grafts: Allogeneic Stem Cell Transplant for HIV+ /AML Patient: A Case Report from the Impaact P1107 Observational Study 2018 ·Blood ·Jingmei Hsu, Marshall J. Glesby, Tsiporah B. Shore, Catherine B. Small, Usama Gergis, Sebastian Mayer, Adrienne A. Phillips, Lawrence D. Petz, Renee Browning, Meredith G. Warshaw, Deborah Persaud, (unknown), Koen van Besien	0
10	Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) 2018 ·Clinical Trials ·Rakesh Awasthi, Constantine S. Tam, Ulrich Jaeger, Samantha Jaglowski, S.R. Foley, Koen van Besien, Nina D. Wagner‐Johnston, (unknown), Stephen J. Schuster, Gilles Salles, Richard T. Maziarz, Özlem Anak, Lida Pacaud, Lucien Gazi, Edward Waldron, Jason S. Hamilton, (unknown), Feng Tai, Karen Thudium Mueller, Edmund K. Waller	0
11	Mycobacterial spindle cell pseudotumour: epidemiology and clinical outcomes 2018 ·Journal of Clinical Pathology ·Maroun M. Sfeir, Audrey N. Schuetz, Koen van Besien, Alain Borczuk, Rosemary Soave, Stephen G. Jenkins, Thomas J. Walsh, Catherine B. Small	19
12	Kidney Dysfunction Post-Allogeneic Transplant: High Incidence of TMA and Kidney GvHD 2017 ·Blood ·Hannah Choe, (unknown), Usama Gergis, Tsiporah B. Shore, Sebastian Mayer, Jingmei Hsu, Adrienne A. Phillips, Surya V. Seshan, Thangamani Muthukumar, Koen van Besien	1
13	Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells (HPCs) for Globin Gene Transfer in Patients with Sickle Cell Disease 2017 ·Blood ·Farid Boulad, Tsiporah B. Shore, Koen van Besien, (unknown), (unknown), Caterina P. Minniti, (unknown), Fabiana Perna, Xiuyan Wang, Isabelle Rivière, Michel Sadelain, Patricia A. Shi	3
14	Safe and Effective Implementation of a Red Blood Cell (RBC) Transfusion Hemoglobin (Hb) Threshold of 7 g/Dl on an Inpatient Stem Cell Transplant Unit: A Single Institution Experience 2017 ·Blood ·Melissa M. Cushing, Ljiljana V. Vasović, Kathleen Kane, Usama Gergis, Adriana Rossi, Adrienne A. Phillips, Yen‐Michael S. Hsu, (unknown), Sebastian Mayer, Jingmei Hsu, Sang‐Min Lee, Tsiporah B. Shore, Koen van Besien, Ruchika Goel	1
15	Clinical Pharmacology of CTL019 in Patients with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) 2017 ·Blood ·Rakesh Awasthi, Constantine S. Tam, Ulrich Jaeger, Samantha Jaglowski, S.R. Foley, Koen van Besien, Nina D. Wagner‐Johnston, Marie José Kersten, Stephen J. Schuster, Gilles Salles, Richard T. Maziarz, Oezlem Anak, Lida Pacaud, Lucien Gazi, Edward Waldron, Jason S. Hamilton, (unknown), Feng Tai, Karen Thudium Mueller, Edmund K. Waller	1
16	Novel Risk Factors for Epstein-Barr Virus (EBV) Reactivation and Post-Transplant Lymphoproliferative Disorder (PTLD) after Allogeneic Hematopoietic Stem Cell Transplant 2017 ·Blood ·(unknown), Tsiporah B. Shore, Usama Gergis, Jingmei Hsu, Adrienne A. Phillips, Sebastian Mayer, Hanna Rennert, Koen van Besien	3
17	Infectious Disease Pathology 2014 ·Modern Pathology ·Jiehao Zhou, Koen van Besien, Attilio Orazi, Ethel Cesarman, Dan Knowles, Julia T. Geyer, Dao‐Xiu Zhou, (unknown), Vladimir Rodic, John Downie, Amanda Termuhlen, Mark A. Lones, Minnie Abromowitch, S L Perkins	12
18	Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation 2006 ·Biology of Blood and Marrow Transplantation ·Willis H. Navarro, Fausto R. Loberiza, Ruta Bajorunaite, Koen van Besien, Julie M. Vose, Hillard M. Lazarus, J. Douglas Rizzo	79
19	Randomized comparison of frontline alternating chemotherapy versus brief induction followed by autologous stem cell transplant for aggressive lymphomas 2003 ·Blood ·Maria Alma Rodriguez, Koen van Besien, Fredrick B. Hagemeister, Sergio Giralt, Peter McLaughlin, James Gajewski, Jorge Romaguera, Issa F. Khouri, Anas Younes, Fernando Cabanillas, Richard E. Champlin	2
20	Cutting Edge: Activation of the p38 Mitogen-Activated Protein Kinase Signaling Pathway Mediates Cytokine-Induced Hemopoietic Suppression in Aplastic Anemia 2002 ·The Journal of Immunology ·Amit Verma, Dilip K. Deb, Antonella Sassano, Suman Kambhampati, Amittha Wickrema, Shahab Uddin, Mani Mohindru, Koen van Besien, Leonidas C. Platanias	74

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact